icon-folder.gif   Conference Reports for NATAP  
 
  17th European AIDS Conference
November 6-9
2019, Basel
Back grey_arrow_rt.gif
 
 
 
Aging with HIV
 
 
  Giovanni Guaraldi, MD
Reported by Jules Levin
EACS Nov 2019, Basel
 
Download the PDF here
 
Download the PDF here
 

0122201

0122202

0122203

0122204

0122205

There is a thought held by some researchers that earlier ART may reduce comorbidities risks, but I maintain earlier ART will not reduce the risk that much & what about PLWH who do NOT start early as is the case despite Guidelines' recommendations to start immediately & the CDC reports only 50% have viral suppression, its 73% in WIHS. This as yet to be studied as far as I know: comparing these 2 groups. Particularly with the recent association with weight gain & integrase & its affects on CVD, diabetes, and fatty liver this raises more concern than was thought prior to this recent discovery. Jules
 
We performed a case-control study including antiretroviral therapy (ART)-experienced patients who were HIV seropositive for 20.6 years ("HIV-Aging"), or who were seropositive for < 11.3 years ("HIV-Aged") having access in 2013 at the Modena HIV Metabolic Clinic. Patients were matched in a 1:3 ratio with controls from the CINECA ARNO database. MM was defined as the concurrent presence of >2 NICM. Logistic regression models were constructed to evaluate associated predictors of NICM and MM.
 
We analysed 404 HIV-Aging and 404 HIV-Aged participants in comparison to 2424 controls. The mean age was 46.7±6.2 years, 28.9% were women. Prevalence of HIV co-morbidities and MM were significantly higher in the HIV-positive groups compared to the general population (p<0.001) and a trend towards higher rates of MM was found in aging vs aged group. This difference turned to be significant in patients above the age of 45 years old (p<0.001).
 
In multivariable models including age, gender, and nadir CD4 count, we observed 5-fold increased odds ofMM in HIV-Aging participants compared to HIV-negative individuals (OR = 5.0, 95% CI,3.3-7.6, p<0.01), and 4-fold increased odds of MMin HIV-Aged participants compared to HIV-negative (OR = 3.8, 95% CI,2.5-6.0, p<0.01) (Fig 3). In the subset of HIV patients over-45 years old, including 502 individuals, prevalence of MMin HIV-Aged vs. HIV-Aging was 42% and 58%, (p = 0.181). In multivariable logistic regression we documented a statistically significant increased risk of MMin HIV-Aging compared to HIV-Aged patients (OR 1.92, 95% C.I. 1.03-3.56, p = 0.039) after adjustment for gender (OR 3.46, 95% C.I. 1.19-10.04, p = 0.023), age (per 1 yr increase OR 1.08, 95% C.I. 1.02-1.14, p = 0.004), lipodystrophy, and cumulative exposure to ARVs (Fig 4). CONCLUSION: People aging with HIV display heterogeneous health conditions. Host factors and duration of HIV infection are associated with increased risk of MM compared to the general population.
 
Pdf publication attached

0122206

0122207

0122208

0122209

01222010

01222011